Recursion Pharmaceuticals
RXRX
84 hedge funds and large institutions have $1.26B invested in Recursion Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 11 reducing their positions, and 7 closing their positions.
291% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 11
248% more call options, than puts
Call options by funds: $1.48M | Put options by funds: $425K
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
12% more funds holding
Funds holding: 75 → 84 (+9)
6.63% more ownership
Funds ownership: 27.91% → 34.53% (+6.6%)
26% less capital invested
Capital invested by funds: $1.71B → $1.26B (-$451M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$100M |
| 2 |
State Street
Boston,
Massachusetts
|
+$35.9M |
| 3 |
Mitsubishi UFJ Trust & Banking
Tokyo,
Japan
|
+$11.3M |
| 4 |
YRHAM
Yong Rong (HK) Asset Management
Sheung Wan,
Hong Kong
|
+$10.7M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$9.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.13M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$2.27M |
| 3 |
RCM
Ratan Capital Management
Miami Beach,
Florida
|
-$2.12M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$730K |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$642K |
RXRX Hedge Fund Activity: Q3 2021 in Review
84 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q3 2021, worth a combined $1.26B — down 26% from $1.71B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new RXRX positions and 7 closed out — a net gain of 10 holders — while 43 added to existing stakes and 11 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $100M. The largest seller was Fidelity Investments, cutting an estimated $7.13M.
- 84 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q3 2021, up from 75 in Q2 2021.
- Funds reported $1.26B of Recursion Pharmaceuticals stock for Q3 2021, down 26% quarter-over-quarter.
- 17 funds opened new Recursion Pharmaceuticals positions in Q3 2021 and 7 closed out, a net change of +10 holders.
- The largest Recursion Pharmaceuticals buyer in Q3 2021 was Baillie Gifford & Co, an estimated $100M added.
- The largest Recursion Pharmaceuticals seller in Q3 2021 was Fidelity Investments, an estimated $7.13M sold.
Based on aggregated 13F filings for Q3 2021.